Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Mymetics Corp

Market Cap 439K 379K 349K 327K 614K 41.73M 623K 4.14M 1.61M 20.3M 1.65M 1.61M 70.28M P/E Ratio 2021
-1.86x
P/E Ratio 2022 -1.77x
Enterprise Value 72.12M 62.35M 57.44M 53.8M 101M 6.86B 102M 681M 265M 3.34B 271M 265M 11.55B EV / Sales 2021
177x
EV / Sales 2022 78x
Free-Float
99.88%
Yield 2021 *
-
Yield 2022 -
Manager TitleAgeSince
Chief Executive Officer 58 19/11/2012
Change 5-day change 1-year change 3-year change Capi.($)
-11.43%+44.21% - - 45
+1.03%+2.30%+54.92%+111.78% 56.42B
+2.72%+3.26%+47.26%+47.26% 44.54B
+1.12%+2.79%-13.71%-17.53% 22.9B
+1.17%+3.85%+1.00%+401.79% 21.21B
+3.81%-5.07%+12.00%-29.52% 16.4B
+0.15%+2.24%+9.10%-40.04% 15.4B
-0.69%+0.82%+27.17%+178.31% 13.35B
+5.27%+5.54%+14.25% - 12.36B
+1.61%+1.28%+92.88%+215.31% 11.15B
Average +0.48%+2.09%+27.21%+108.42% 23.75B
Weighted average by Cap. +1.72%+2.37%+31.92%+100.38%

Financials

2021 2022
Net sales 430K 372K 342K 321K 602K 40.89M 611K 4.06M 1.58M 19.89M 1.61M 1.58M 68.88M 1.03M 889K 819K 767K 1.44M 97.76M 1.46M 9.7M 3.77M 47.55M 3.86M 3.78M 165M
Net income -4.73M -4.09M -3.77M -3.53M -6.62M -450M -6.72M -44.64M -17.37M -219M -17.75M -17.37M -758M -4.8M -4.15M -3.83M -3.58M -6.72M -457M -6.82M -45.34M -17.64M -222M -18.03M -17.65M -770M
Net Debt 67.1M 58.01M 53.44M 50.05M 93.87M 6.38B 95.27M 633M 246M 3.1B 252M 246M 10.75B 71.68M 61.97M 57.09M 53.47M 100M 6.82B 102M 676M 263M 3.32B 269M 263M 11.48B
Logo Mymetics Corp
Mymetics Corporation is a vaccine company. The Company is focused on developing vaccines for infectious diseases. The Company has over five vaccine candidates in its pipeline: human immunodeficiency virus type 1 (HIV-1)/acquired immune deficiency syndrome (AIDS), intra nasal Influenza, Malaria, Herpes Simplex Virus (HSV) and the Respiratory Syncitial Virus (RSV) vaccine. Its technology utilizes virosomes, lipid-based carriers containing functional fusion viral proteins and natural membrane proteins, in combination with rationally designed antigens. Its prophylactic HIV-1 vaccine candidate is constituted of virosomes linked to conserved antigens derived from the HIV-1 glycoprotein 41 (gp41) proteins from the clade B. The RSV vaccine consists of the reconstituted membrane of RSV containing the native viral proteins. The HSV vaccine candidate consists of the reconstituted membrane of HSV-1 or HSV-2. The intranasal influenza vaccine includes the reconstituted membrane of influenza virus.
Employees
-
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!